Lecture 9/10: Methods/Vaccines Flashcards
ELISA
Enzyme Linked ImmunoabSorbent Assay; Ag/Ab quantification
Flow cytometry
IDs specific cell types w/ lasers and fluorescent Abs
Agglutination
Cell/molecule clumping when Ab is bound
Analyte
Molecule you want to measure
Polyclonal Abs
- Mix of Abs from different B cell clones
- Most IgG -> poly clonal response
- Recognize different epitopes on same pathogen
- Change over time for different Ags or increased affinity
Monoclonal Abs
- Abs derived from 1 clone
- No affinity maturation or change in antigen
- Consistent response for diagnosis and therapy
Creating mAbs
Mice: mix spleen cells w/ cancer cells -> fused immortal hybridoma B cell clone
Humans: isolate desired clones, fuse w/ immortal myeloma
Agglutination test
E.g. Coombs test; positive or negative
- Detects Abs to RBC Rh factor, anti-Hu IgG binds mom’s anti-Rh IgG -> RBC agglutination
Types of ELISA
Direct: detect/quantify Abs
Indirect (sandwich): detect/quantify Ags
Direct ELISA
Ag bound on plate, detected w/ Ab
Indirect (sandwich) ELISA
Ag binds surface-coated primary anti-Ag Ab -> wash -> secondary anti-Ag Ab w/ tag gives signal
Visualization with tags vs probes
Tags: enyme tag adds colored substrate e.g. HRP; ELISA, IHC
Probes: fluorescent probes allow direct visualization of fluorescence e.g. FITC, Rhodamine; ELISA, immunofluor., flow
Serology
Measuring analytes in serum (soluble portion of CLOTTED blood post-centrifuge; plasma = anti-coag. blood post-centrifuge)
Titer
Last dilution above background
Concentration
Actual Ag amount
Absorbance
Dye concentration
Lateral flow assay
e.g. at-home COVID test
- Conjugate pad w/ primary labeled Ab
- Test line w/ unlabeled other primary Ab
- Control line w/ secondary Ab
- Flow through generates lines
Western Blot
Separate proteins by weight, transfer to membrane, Abs to visualize
IHC/IF
- Visualize cell/tissue morph. w/ light or fluorescence microscopy
1. Prep slide
2. Add primary mouse anti-Ag Ab
3. Add labelled secondary anti-Ab HRP
4. Add substrate for enzyme
5. Color visual
Types of immunization
- Passive
- Active
Passive immunization
Providing preformed Abs to patient (faster, rabies, antivenom treatment)
Active immunization
Using own immune system to make Abs T cells (vaccines)
Types of vaccines
- Live attenuated
- Conjugate
- Toxoid
- Pathogen subunits
- Dead whole organisms
- mRNA
- DNA
Live attenuated vaccine
MMR, Rotavirus, Varicella, Influ. nasal, oral polio, BCG
- Pros: long lasting immunity, similar or same immune response, diverse Abs generated
- Cons: can’t give to immunocomp.; pathogenic reversion
Conjugate vaccine
Hemophilus influ. type b, pneumococcal conjugate
Protein conjugated to polysaccharide -> T dependent response
Toxoid vaccine
Diptheria, tetanus
Vaccine w/ toxoids similar to pathogen toxins; immune response cross-reacts and neutralizes actual toxin
Subunit vaccine
Vax w/ part of pathogen i.e. purified protein, recombinant protein, polysacch., peptides, etc.
- Pros: safe, easier quality control
- Cons: might not work or be as long lasting
Multivalent vaccines
Subunit w/ combo of different subunits in 1 for different strains.
Subunit req. proper config. for protection (e.g. RSV failure)
Killed whole organism vaccines
Pathogen inactivated w/ chemicals, heat, etc.
e.g. hepatitis, rabies, some flu
Can be very immunogenic, v. effective
Combo vaccines
Multiple methods e.g. DTaP
Toxoid: diptheria, tetanus
Subunit: acellular proteins
mRNA vaccines
Moderna, Pfizer
Encapsulated mRNA facilitating DC uptake -> protein expression -> presentation
Adenoviral (DNA) vaccine
J&J
Disabled adenovirus delivers spike protein DNA; more stable vs mRNA but less immunogenic
Adjuvants
Vaccine agents that enhance immune response via innate immunity; stim. DC cytokine secretion
- IL-12 -> Th1 diff. -> B support
- IL-6 -> B cell prolif.
- IFN-gamma -> stim. class switch, Ab response
- Upreg. CD28 express.
Clinical trial phases
- Pre-clinical
- Phase I
- Phase II/III
Pre-clinical phase
Experimental animals for safety/efficacy
Phase I trials
Safety + dose escalation; <10 pts often w/ dose escalation, open label, no vulnerable popns
Phase II/III
Test for efficacy; more subjects, randomized, controlled, double blind
Challenge study
Challenge immunized pts w/ live pathogen; helpful w/ low disease incidence